July AJMC author Anuraag R. Kansal, PhD, explains how metastatic cancer diagnoses drive Medicaid spending and why earlier screening could lower costs.
Anuraag Kansal, PhD
Advertisement
Articles by Anuraag Kansal, PhD
An economic model based on the ECHELON-2 trial demonstrated cost-effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma (PTCL).
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Trump Childhood Vaccine Order: What It Means for Parents and Payers
2
FDA Proposes GRAS Rule, Advances Ultra-Processed Food Definition
3
Orelabrutinib Cuts Progression Risk 68% in Frontline CLL/SLL
4
Extreme Heat May Increase Microplastic Exposure, Related Health Concerns: Eva R. Parker, MD
5